Authors: Volynets G, Skyortsowa TA, Ptapov AS, et al.
Published in: EASL, 19th – 23rd April 2017, Amsterdam
Authors: Majekodunmi AO, Thorne C, Malyuta R, et al.
Published in: Pediatr Infect Dis J. 2017;36(5):e123-e129
Objective To compare CD4 T cell recovery in HIV/HCV coinfected children with recovery in HIV monoinfected children.
Authors: Indolfi G, Thorne C, El-Sayed MH, Giaquinto C, Gonzalez-Peralta RP.
Published in: J Pediatr Gastroenterol Nutr. 2017;64(6):851-854
Abstract The development of oral hepatitis C virus (HCV) direct-acting antivirals (DAAs) has revolutionized the therapeutic field. Nowadays, multiple safe and highly effective antiviral regimens are commercially available to treat adults with hepatitis C infection.
Authors: Thorne C, Indolfi G, Turkova A, Giaquinto C, Nastouli E.
Published in: J Virus Erad. 2015 Jul 1;1(3):203-5.
Abstract Hepatitis C virus infection is a leading cause of liver-related morbidity and mortality. In the paediatric population, HCV infection is underdiagnosed and undertreated in the absence of robust screening policies worldwide, and a lack of tolerable,
Authors: Turkova A, Giacomet V, Goetghebuer T, et al.
Published in: J Virus Erad. 2015;1(3):179-184
Objectives To describe use of treatment for chronic hepatitis C virus (HCV) infection in HIV/HCV co-infected children and young people living in Europe and to evaluate treatment outcomes.
Methods HCV treatment data on children and young people aged <25 years with HIV/HCV co-infection were collected in a cohort collaboration of 11 European paediatric HIV cohorts.